OBIGEN PHARMA has achieved the objectives of interim analysis for Phase 2 clinical trial of OBI-858

OBIGEN Pharma Appoints New CEO to Lead IPO Growth

OBIGEN and A Phase I Clinical Trial Physician Present New 760 kDa Taiwan Botulinum Toxin at AMWC Japan 2024

OBI-858 Approved by INTELLECTUAL PROPERTY CORPORATION OF MALAYSIA (MyIPO), No. MY-205101-A

OBI-858 Approved by TAIPEI GRAND MOSQUE FOUNDATION For Halal Certificate No. TGM.N13-240702-250831-01B55-1

OBI-858 Approved by Indonesia DIRECTORATE GENERAL OF INTELLECTUAL PROPERTY, No. HKI-3-KI.05.01.08-DP-P00202109681

TFDA CLEARS OBI-858’S IND APPLICATION FOR PHASE II HUMAN CLINICAL TRIAL

Filing of Phase II Human Clinical Trial Application for OBI-858 to Taiwan Food and Drug Administration (TFDA)

OBI-858 Approved by Saudi Authority for Intellectual Property (SAIP), No.521430958

Institutional Director of OBI Pharma Changes Its Representative